Flurbiprofen in the subglottic space to prevent postoperative sore throat after cardiac surgery: A randomized double-blind study.

Endotracheal intubation Flurbiprofen Hoarseness Sore throat

Journal

Journal of clinical anesthesia
ISSN: 1873-4529
Titre abrégé: J Clin Anesth
Pays: United States
ID NLM: 8812166

Informations de publication

Date de publication:
01 Mar 2024
Historique:
received: 01 10 2023
revised: 29 01 2024
accepted: 15 02 2024
medline: 3 3 2024
pubmed: 3 3 2024
entrez: 2 3 2024
Statut: aheadofprint

Résumé

Postoperative sore throat (POST) and hoarseness are common complications of tracheal intubation. This study aims to evaluate the efficacy of flurbiprofen administered through the subglottic port of tracheal tubes to prevent POST after cardiac surgery. Single-center, prospective, randomized, double-blind, placebo-controlled trial. Tertiary Care Referral University Hospital (Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome). Included 71 patients undergoing for elective cardiac surgery. Inclusion criteria were (a) age between 50 and 75 years, (b) NYHA class I or II, (c) surgery for myocardial revascularization or valve repair or replacement under cardiopulmonary bypass. Patients were double blind randomized to receive flurbiprofen or saline in the subglottic port of the endotracheal tube (groups F and P). The solution was injected ten minutes after tracheal tube placement, ten minutes after ICU admission and ten minutes before tracheal tube removal. The primary outcome was to assess the effect of topical flurbiprofen administered through the subglottic port of the tracheal tube to prevent post-operative sore throat (POST). The secondary outcomes were the presence of hoarseness safety and patient's subjective satisfaction with their recovery. We did not report any exploratory outcomes. We analyzed 68 patients, 34 patients in each group. In group F, two patients complained of POST and hoarseness (5.9%), while all controls did. The two groups significantly differed in the severity scores (VAS and TPS for sore throat and HOAR for hoarseness) at all time points. In group P, patients reported mild to moderate symptoms that significantly improved or disappeared 36 h after tracheal tube removal. According to the multivariable model, hoarseness affected women less than men, in the control group (p = 0.002). None of the patients in either group reported any adverse effects. Repeated administration of flurbiprofen through the subglottic port of tracheal tubes reduced the incidence of sore throat and hoarseness after cardiac surgery without evidence of complications.

Identifiants

pubmed: 38430636
pii: S0952-8180(24)00045-X
doi: 10.1016/j.jclinane.2024.111418
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111418

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Maria Calabrese (M)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Gabriella Arlotta (G)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Maria Enrica Antoniucci (ME)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Luca Montini (L)

Department of Intensive Care Medicine and Anesthesiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: luca.montini@policlinicogemelli.it.

Diana Giannarelli (D)

Facility Epidemiology and Biostatistics, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy.

Temistocle Taccheri (T)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Filippo Corsi (F)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Stefano De Paulis (S)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Andrea Scapigliati (A)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Francesca Bevilacqua (F)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Joel Vargas (J)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Michele Corrado (M)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Natalia Pavone (N)

Department of Cardiovascular Sciences, Cardiac Surgery Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Piergiorgio Bruno (P)

Department of Cardiovascular Sciences, Cardiac Surgery Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Massimo Massetti (M)

Department of Cardiovascular Sciences, Cardiac Surgery Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Franco Cavaliere (F)

Department of Cardiovascular Sciences, Intensive Care Unit, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Classifications MeSH